Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $54.33 Average PT from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $54.33.

A number of brokerages have recently issued reports on CLDX. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They set an “overweight” rating and a $46.00 price objective on the stock. UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $44.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $16.84 on Monday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.55 and a beta of 1.59. The business has a 50 day moving average of $19.99 and a 200 day moving average of $24.37. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. As a group, sell-side analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of CLDX. Apella Capital LLC bought a new position in Celldex Therapeutics in the first quarter worth about $309,000. Mirador Capital Partners LP raised its position in shares of Celldex Therapeutics by 7.0% in the 1st quarter. Mirador Capital Partners LP now owns 127,874 shares of the biopharmaceutical company’s stock worth $2,321,000 after acquiring an additional 8,382 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Celldex Therapeutics by 6.9% in the 1st quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company’s stock valued at $1,784,000 after purchasing an additional 6,327 shares during the period. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 2,933 shares in the last quarter. Finally, Polar Asset Management Partners Inc. grew its stake in Celldex Therapeutics by 1,318.0% in the fourth quarter. Polar Asset Management Partners Inc. now owns 137,550 shares of the biopharmaceutical company’s stock worth $3,476,000 after purchasing an additional 127,850 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.